An Exogenous Ketone Ester Slows Tumor Progression in Murine Breast and Renal Cancer Models
Authors:
- Henry Nnaemeka OgbonnaHOHenry Nnaemeka Ogbonna
- Zachary RobertsZRZachary Roberts
- Nicholas GodwinNGNicholas Godwin
- Pia MuriPMPia Muri
- William J. TurbittWTWilliam J. Turbitt
- Zoey N. SwalleyZSZoey N. Swalley
- Francesca R. DempseyFDFrancesca R. Dempsey
- Holly R. StephensHSHolly R. Stephens
- Jianqing ZhangJianqing Zhang
- Eric P. PlaisanceEric P. Plaisance
- Lyse A. NorianLyse A. Norian
Open Access
Abstract
Background/Objectives: Ketone esters (KEs) exhibit promise as anti-cancer agents but their impact on spontaneous metastases remains poorly understood. Although consumption of a ketogenic diet (KD) that is low in carbohydrates and high in fats can lead to KE production in vivo, the restrictive composition of KDs may diminish adherence in cancer patients. Methods: We investigated the effects of an exogenous ketone ester-supplemented (eKET), carbohydrate-replete diet on tumor growth, metastasis, and underlying mechanisms in orthotopic models of metastatic breast (4T1-Luc) and renal (Renca-Luc) carcinomas. Mice were randomized to diet after tumor challenge. Results: Administration of KEs did not alter tumor cell growth in vitro. However, in mice, our eKET diet increased circulating β-hydroxybutyrate and inhibited primary tumor growth and lung metastasis in both models. Body composition analysis illustrated the overall safety of eKET diet use, although it was associated with a loss of fat mass in mice with renal tumors. Immunogenetic profiling revealed divergent intratumoral eKET-related changes by tumor type. In mammary tumors, Wnt and TGFβ pathways were downregulated, whereas in renal tumors, genes related to hypoxia and DNA damage repair were downregulated. Conclusions: Thus, our eKET diet exerts potent antitumor and antimetastatic effects in both breast and renal cancer models, albeit with different modes of action and physiologic effects. Its potential as an adjuvant dietary approach for patients with diverse cancer types should be explored further.Keywords
Funding Information
- NIH (R01 349979.01.01.2027166.10, T32HL105349)
- UAB O’Neal Invests Comprehensive Cancer Center (R01 349979.01.01.2027166.10, T32HL105349)
- NHLBI (R01 349979.01.01.2027166.10, T32HL105349)
This publication has 47 references indexed in Scilit:
- Metabolic reprogramming in cancer: Mechanisms and therapeuticsMedcomm, 2023
- HIF1A predicts the efficacy of anti-PD-1 therapy in advanced clear cell renal cell carcinomaTranslational Oncology, 2022
- Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growthMed, 2022
- Impact of ketogenic diet and ketone diester supplementation on body weight, blood glucose, and ketones in Sprague Dawley rats fed over two weeksFood Chemistry: Molecular Sciences, 2021
- Biotinylated Streptavidin Surface Coating Improves the Efficacy of a PLGA Microparticle-Based Cancer VaccineBioconjugate Chemistry, 2020
- Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and TherapeuticsCell Metabolism, 2017
- Hypoxia, Hypoxia-inducible Transcription Factors, and Renal CancerEuropean Urology, 2016
- The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory diseaseNature Medicine, 2015
- Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancerInternational Journal of Cancer, 2014
- Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: Association with tumor-derived growth factorsExperimental and Molecular Pathology, 2007